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dentifying the mechanisms and lifetime tra-
jectory of schizophrenia is one of the major challenges
of schizophrenia research. Kraepelin’s original delin-
eation of its lifetime trajectory prevailed for nearly a
century. His description of schizophrenia emphasized
that this disorder caused a deterioration in cognitive
function that began at an early age (“dementia prae-
cox"”) and that it was an early-onset neurodegenerative
disorder similar to the late-onset neurodegenerative dis-
order discovered by his colleague Alois Alzheimer.
1 He
believed that dementia praecox was a brain disease that
could be localized in frontal and temporal regions. He
and his colleagues searched in vain for a neuropatho-
logical signature that was comparable to the plaques
and tangles of Alzheimer's disease. Despite the lack of
an identified neuropathology, for most of the 20th cen-
tury schizophrenia was assumed to be a dementia-like
disease that was characterized by a deteriorating course.
Among biologically oriented psychiatrists, it was
assumed that this course reflected an underlying dete-
rioration in the brain.
The advent of neuroimaging technologies offered the
possibility that they might provide a noninvasive way for
tracking neurodegenerative processes in schizophrenia
in vivo. Computerized tomography (CT) scanning was
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Defining the lifetime trajectory of schizophrenia and the
mechanisms that drive it is one of the major challenges of
schizophrenia research. Kraepelin assumed that the mech-
anisms were neurodegenerative (“dementia praecox”), and
the early imaging work using computerized tomography
seemed to support this model. Prominent ventricular
enlargement and increased cerebrospinal fluid on the brain
surface suggested that the brain had atrophied. In the
1980s, however, both neuropathological findings and evi-
dence from magnetic resonance imaging (MRI) provided
evidence suggesting that neurodevelopmental mechanisms
might be a better explanation. This model is supported by
both clinical and MRI evidence, particularly the fact that
brain abnormalities are already present in first-episode
patients. However, longitudinal studies of these patients
have found evidence that brain tissue is also lost during the
years after onset. The most parsimonious explanation of
these findings is that neurodevelopment is a process that is
ongoing throughout life, and that schizophrenia occurs as
a consequence of aberrations in neurodevelopmental
processes that could occur at various stages of life.   
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PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:40  Page 409the first modality to be applied to in vivo studies of the
brain in schizophrenia, and it seemed to provide confir-
mation for the Kraepelinian view. Beginning with the
Northwick Park study in 1975, a steady series of reports
appeared, describing“brain atrophy” in schizophrenia.
2-4
Although CT provided images of the brain that were
striking in the 1970s and early 1980s, because the human
brain could be directly visualized and measured in vivo
for the first time, its limitations may in fact have been
misleading. The early CT scans only permitted visual-
ization of brain parenchyma and cerebrospinal fluid
(CSF). The inherent limitations of CT scanning con-
tributed to the belief that the brain had atrophied. The
main finding was that patients had enlargement of the
ventricular system and an increase in CSF on the brain
surface, in a pattern that was quite similar to Alzheimer's
disease. By inference, as in Alzheimer's disease, patients
with schizophrenia had lost brain tissue that was once
present.
Early forerunners of the 
neurodevelopmental hypothesis
During this time, however, a modest minority view was
being presented by individuals who looked primarily at
the developmental trajectory of the illness and gener-
ated hypotheses based on its age of onset and other
early characteristics. In the 1970s Barbara Fish sug-
gested that schizophrenia might be a consequence of a
congentital inherited neurointegrative defect that she
referred to as “pandysmaturation” or “pandevelop-
mental retardation.”
5 She based her argument on her
observations of premorbid indicators of pathology in
children who developed schizophrenia, particularly
when they were from affected families and carried a
genetic vulnerability. She noted that many children who
later develop schizophrenia have a variety of motor,
cognitive, language, and social impairments. Her dis-
cussion of pandysmaturation presages much of the work
that is considered to be au courant today: the use of the
concept of “biomarkers,” an emphasis on early identifi-
cation and treatment prior to the emergence of psy-
chosis, use of epidemiological data such as IQ tests
administered to military inductees prior to onset to
identify “at-risk” individuals, and a discussion of how
pregnancy complications and birth injuries might con-
tribute to the development of schizophrenia. Her work
epitomizes one perspective on the developmental tra-
jectory of schizophrenia; as a child psychiatrist, she
emphasizes the role of maturational processes occurring
early in development, a view that has sometimes been
called “doomed from the womb.”
Another remarkably prescient hypothesis concerning
neurodevelopmental factors and schizophrenia was
advanced by Irwin Feinberg, who in 1983 proposed that
schizophrenia might be “caused by a fault in pro-
grammed synaptic elimination during adolescence.”
6
While Fish emphasized the importance of genetic vul-
nerability and markers that appeared during early child-
hood, Feinberg argued that the crucial period for the
development of schizophrenia occurred during the teens
and 20s, when brain maturation is occurring rapidly and
when the disorder has its most characteristic age of
onset. Working as a sleep researcher, he had noted that
normal adolescents exhibit striking changes in sleep
architecture and event-related potentials, as measured
by electroencephalography (EEG). He also drew on
early observations that brain metabolic rate, measured
using the nitrous oxide method, declines during adoles-
cence and inferred that this might reflect the occurrence
of a major change in brain organization.
7 Drawing on
Huttenlocher's studies showing that synaptic density
decreases during adolescence,
8 presumably due to prun-
ing back of gray matter (GM), he inferred that the
brain's decreased metabolic needs during normal ado-
lescence were due to a paradoxical process that elimi-
nated synapses and yet also increased efficiency of cog-
nitive processing. He then proceeded to suggest that
schizophrenia occurs as a consequence of a defect in a
gene/protein that regulates neurodevelopmental
processes such as synaptic pruning, and nerve growth
factor (NGF) is cited as a possible example:
The control [over synaptic elimination] may be exercised
by determining the availability of, or the requirements for,
the trophic factor that maintains synaptic connections.... As
a result of some abnormality in this process, too many, too
few or the wrong synapses are eliminated. (Regrettably, we
have no basis to choose among these possibilities.) As a
consequence of this “bug” in the genetic program, defects
of neuronal integration develop, producing the sympto-
matology of schizophrenia. (p 331)
This seminal paper thus laid the groundwork for an
alternative view: schizophrenia is a neurodevelopmen-
tal disorder that arises during adolescence or young
adulthood because of an aberration in the genetic regu-
lation of brain maturation.
Clinical research
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resonance imaging and the 
re-emergence of neuropathology
When magnetic resonance imaging (MRI) emerged as a
new imaging modality in the early to mid-1980s, a pow-
erful tool became available to study the human brain in
health and disease. Unlike CT, MRI provided exquisite
anatomic detail, with clear differentiation of tissues such
as GM, WM, and CSF. Subcortical structures were also
clearly visible, such as caudate, putamen, globus pallidus,
thalamus, and hippocampus. Visualization of cerebral
sulci permitted the delineation of lobes and Brodmann
areas. Because MRI did not entail any exposure to ion-
izing radiation (unlike CT), new research options were
available, such as the study of children or the use of
repeated scans to track brain development or brain
aging. 
MRI studies of schizophrenia quickly provided evidence
to support the primacy of the neurodevelopmental
hypothesis. The first quantitative case-control MRI study
of schizophrenia appeared in 1986.
9 It used the superior
anatomic resolution of MR to measure frontal lobe size
in addition to cerebral and cranial size; it found that all
of these structures were significantly smaller in patients
than in controls, and that these decreases were related
to negative symptoms and cognitive impairment.
Because cranial expansion occurs secondary to cerebral
growth, the study suggested that patients with schizo-
phrenia may have some type of early developmental
abnormality. 
...the present findings suggest that patients suffering from
schizophrenia may have had some type of early develop-
mental abnormality that led to impaired capacity of the
brain to grow, thereby causing a correspondingly small cra-
nial area. This could, of course, be due to a variety of fac-
tors, such as genetics, maternal nutrition, maternal alcohol
consumption, difficulties during delivery, or environmental
factors (eg, nutrition and infections) during the first year
of life. (p 142-143)
The findings were not consistent with an atrophic
process, through which brain tissue was lost over time.
The findings of decreased frontal, cerebral, and cranial
size were subsequently repeatedly confirmed, as were
the relevance of the various potential causes of early
neurodevelopmental abnormalities.
10-22
At the same time (and in the same issue of Archives of
General Psychiatry) new neuropathology data also
emerged that provided indirect support for the neu-
rodevelopmental hypothesis. Benes et al conducted
quantitative analyses of glial density, neuron-glia ratios,
and neuronal size in the prefrontal, anterior cingulate,
and primary motor cortex.
23Their findings did not meet
neuropathological criteria for evidence of a neurode-
generative/atrophic process: neuronal loss, gliosis, a
decrease in the neuron:glia ratio, and neuronal shrink-
age. Instead they observed reduced numbers of neurons
per unit volume of tissue and a decrease in glia. They
concluded that their findings did not support the pres-
ence of a neurodegenerative process in schizophrenia.
These findings have also been repeatedly confirmed.
24-27
There is now a consensus that the neuropathology of
schizophrenia is defined by increased neuronal density,
a reduction in the dendritic arbor, and cortical thinning. 
Following these reports in 1986, schizophrenia
researchers on both sides of the Atlantic put forth addi-
tional arguments in support of the neurodevelopmental
model, which became increasingly widely accepted.
28-30
In general, most articulations of this model have empha-
sized the importance of very early developmental
processes, which occurred either prior to birth or shortly
afterward. The model assumes that a genetic vulnerabil-
ity may be present, and that this vulnerability is
expressed if a sufficient number of releasing factors con-
verge in the vulnerable individual early in life. Some of
these may occur prior to birth, such as viral infections,
maternal malnutrition, or exposure to toxins in utero;
some may occur shortly after, such as obstetrical com-
plications and birth injuries, or viral infections. These fac-
tors are presumed to injure the developing brain, to
express themselves in the type of neuropathology that
was described in the 1986 Benes study and later ones,
and to create impairments in structural or functional
connectivity that will be the substrate upon which schiz-
ophrenia will develop at a later age. Clinical findings in
support of an early developmental abnormality include
a variety of premorbid indicators or markers, such as
decreased cranial size, motor impairments and neuro-
logical soft signs, and cognitive and social impairments.
These findings have been repeatedly replicated in high-
risk samples or studies of children who later developed
schizophrenia using a variety of ingenious designs.
10-18
During the ensuing years, MR studies also continued to
add to the evidence in support of the neurodevelopmen-
tal hypothesis. Many of the early MR studies examined
samples of convenience, such as institutionalized patients
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brain abnormalities are present in individuals with schiz-
ophrenia at the time of onset (“first-episode patients,”
FEP) provides a crucial test of the hypothesis, since any
abnormalities noted would have presumably antedated
the clinical presentation. Investigators conducting stud-
ies of FEP began to study patients at the time of onset of
illness and to find that many types of brain abnormalities
are present early in the illness. These include decreased
cerebral size, decreased frontal and temporal lobe size,
decreased thalamic size, decreases in GM and WM vol-
ume, and increased CSF on the brain surface and in the
ventricles.
22,31
Does tissue loss continue after onset?
Another critical question about the lifetime trajectory
of schizophrenia and the related concept of neurode-
velopment is whether the brain abnormalities that are
present at onset continue to worsen over time. If patients
with schizophrenia lose tissue at a greater rate than
healthy normals, this could suggest that the disorder also
has a neuroprogressive or neurodegenerative compo-
nent. The optimal way to address this question is to con-
duct longitudinal studies of brain changes over time,
beginning at the time of onset, and to obtain repeated
scans spaced several years apart. Since the brain loses
tissue over time as a consequence of the normal aging
process, a cohort of longitudinally studied normal con-
trols is a mandatory component of this type of study.
Several recent overviews have summarized progress in
the area to date.
31,32 There have been only seven MR
studies that use a prospective longitudinal design.
33-47The
majority of these provide evidence for progression, using
a variety of measures, such as ventricular size, cerebral
volume, grey matter volume, or white matter volume. All
of these studies have had significant limitations, however.
For example, patient sample sizes are typically very
small, usually in the 20s or 30s, and control groups are
even smaller, usually in the 10s to 20s. Surveillance peri-
ods are relatively short, often as small as 1 year.
Therefore, the validity of the conclusions drawn from
these sMR studies has been called into question, and the
magnitude of the changes reported has been considered
implausible; it has been pointed out that if the magni-
tude of changes reported are actually true, patients with
schizophrenia would have very little brain tissue left by
the time that they reach their 50s or 60s.
48
In order to determine whether brain abnormalities pre-
sent at onset continue to progress over time and to
delineate their pattern, a research design that imple-
ments a prospective longitudinal study is necessary.
Optimally such a study should meet several criteria: (i)
a large first episode sample; (ii) a large normal control
sample; (iii) a low attrition rate in both samples in order
to ensure that they are representative; (iv) surveillance
over a sufficiently long time period to determine the pat-
tern and degree of change (ie, a minimum of 5 years, and
preferably 10 to 20); (v) sampling with multiple time
points in order to determine the pattern of change (ie,
linear, nonlinear) and its relation to the time of onset;
(vi) use of multimodal scanning sequences that permit
reliable quantitative measurement of GM, WM, CSF,
lobes, and cortical and subcortical regions. Almost none
of the currently published studies meets these criteria.
Perhaps the strongest is one that has examined 119
patients at 3-year intervals for a period of up to 12 years;
patients were genotyped for the BDNF val/met poly-
morphism (rs6265) in order to examine the impact of a
well-understood neurodevelopmental gene on neuro-
progression; the met allele carriers displayed signifi-
cantly more brain tissue loss on the frontal cortex than
did the val homozygotes.
47
The meaning of "neurodevelopmental" 
and "neuroprogressive"
Some findings about schizophrenia are sufficiently well-
replicated that they can be treated as reasonably well-
established facts. These include the following: (i) schizo-
phrenia has a genetic component; (ii) some individuals
who later develop schizophrenia manifest premorbid
indicators; (iii) the age of onset is typically in the teens
and twenties; (iv) brain abnormalities are present at the
time of onset; (v) brain abnormalities (probably) con-
tinue to progress after onset; (vi) none of these general-
izations applies to all individuals with schizophrenia, and
therefore they are not really “facts” in the sense of being
universally true. However, if we accept these as guides
to our thinking, what conclusions can we draw?
Discussions about the lifetime trajectory of schizophre-
nia may have been hampered by a tendency to ask ques-
tions that oversimplify and polarize. For example, is the
process neurodevelopmental or neuroprogressive (neu-
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to remind ourselves that brain development is an ongo-
ing process that occurs throughout life. Brain develop-
ment is comprised of some processes that typically or
only occur early, such as neuron formation, neuronal
migration, and formation of cortical lamina. Other
processes such as increased myelination and synaptic
pruning occur primarily during adolescence. Yet other
processes such as synaptic plasticity (formation or main-
tenance of dendrites, spines, and synapses) are ongoing
throughout life, even on into old age. All of these are cel-
lular and molecular processes that are regulated by genes,
and probably a very large number of genes that interact
epistatically and that respond to changes in their envi-
ronment. Some genes, such as BDNF or NRG1 or NGF
or RELN, have known neurodevelopment functions that
make them obvious candidates, but many relevant genes
are probably as yet undiscovered. We are still a very long
way from understanding how these processes and neu-
roregulatory genes, or an aberration in them, may lead
the development of schizophrenia or to the measurable
brain changes that have been observed. But that is the
path on which we should be travelling.
Conclusion
In this context the polarities being used to discuss the
lifetime trajectory of schizophrenia seem to be unhelp-
ful. The term “neurodegeneration” is probably not an
appropriate one for referring to ongoing changes in the
brain after onset, since it carries too much heavy bag-
gage by suggesting a similarity between schizophrenia
and classic neurodegenerative disorders such as
Alzheimer's disease or Huntington's disease. It should
probably be replaced with the term “neuroprogression.”
Explaining how the “early developmental” damage
could lie fallow until the teens and twenties has always
been a problem for the “doomed from the womb” for-
mulation, but that problem disappears when we recog-
nize that neurodevelopment is ongoing. Combining a
recognition that abnormalities are present at onset (fur-
ther evidence for neurodevelopment) with a recognition
that changes also occur or continue after onset (neuro-
progression) also ceases to present problems. There
could be a continuation of the same developmental
process (eg, pruning) or a different one (eg, impaired
synaptic plasticity), but in either case the process that
shapes the lifetime trajectory of schizophrenia is funda-
mentally a neurodevelopmental one. ❏
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El curso vital de la esquizofrenia y el 
concepto de neurodesarrollo
Uno de los principales desafíos en la investigación
de la esquizofrenia es la definición de su trayecto-
ria a lo largo de la vida y los mecanismos que la diri-
gen. Kraepelin asumió que los mecanismos eran
neurodegenerativos (“demencia precoz”) y los pri-
meros trabajos con neuroimágenes empleando
tomografía computarizada dieron soporte a este
modelo. El marcado agrandamiento ventricular y el
aumento del líquido céfalo raquídeo en la superfi-
cie del cerebro hicieron suponer una atrofia cere-
bral. Sin embargo, en la década de 1980, ambos
hallazgos neuropatológicos y la evidencia prove-
niente de las imágenes de resonancia magnética
(IRM) aportaron evidencias que sugerían que los
mecanismos del neurodesarrollo constituirían una
mejor explicación. Este modelo se sustenta en evi-
dencias clínicas y de IRM, principalmente por el
hecho que las anormalidades cerebrales ya están
presentes en los pacientes con el primer episodio.
Sin embargo, estudios longitudinales de estos
pacientes han aportado evidencia que el tejido
cerebral también se pierde durante los años que
siguen a la aparición del cuadro. La explicación más
restringida de estos hallazgos es que el neurodesa-
rrollo sería un proceso que se produciría a lo largo
de la vida y que la esquizofrenia occurriría a conse-
cuencia de alteraciones en los procesos de neuro-
desarrollo que podrían presentarse en varias etapas
de la vida. 
La schizophrénie au cours de la vie : 
concept du neurodéveloppement
L’un des principaux défis de la recherche sur la schi-
zophrénie est de définir son parcours durant la vie
et les mécanismes qui le sous-tendent. D’après
Kraepelin, les mécanismes seraient neurodégéné-
ratifs (démence précoce) comme semblaient le
confirmer les premières études d'imagerie réalisées
à l'aide de scanner (tomodensitométrie numérisée).
L’augmentation importante du volume ventriculaire
et l’augmentation de liquide céphalorachidien
extracérébral suggéraient une atrophie cérébrale.
Cependant, dans les années 80, les résultats de la
neuropathologie et les images d’IRM (imagerie par
résonance magnétique) ont prouvé que les méca-
nismes neurodéveloppementaux seraient une
meilleure explication, en particulier par la présence
d’anomalies cérébrales dès les premiers épisodes
symptomatiques. Des études longitudinales effec-
tuées sur les patients présentant une schizophrénie
débutante ont néanmoins montré une perte de
tissu cérébral au cours des années suivant le début
de la maladie. L’explication la plus simple en serait
que, le neurodéveloppement étant un processus
évolutif au cours de la vie, la schizophrénie sur-
viendrait comme une conséquence d’aberrations de
ce processus pouvant intervenir à des stades diffé-
rents de la vie.
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